Literature DB >> 2416837

In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum.

R L Modlin, V Mehra, R Jordan, B R Bloom, T H Rea.   

Abstract

We sought to evaluate cell-mediated immune responses in erythema nodosum leprosum (ENL), a reactional state occurring in lepromatous leprosy. Skin biopsies from patients with leprosy were studied with monoclonal antibodies against T lymphocyte antigenic determinants, interleukin 2 (IL 2), and IL 2 receptors (Tac) by using immunoperoxidase staining of frozen sections. Peripheral blood lymphocytes from 18 ENL patients were tested in vitro for lepromin-induced suppression of Con A stimulation. Serial studies of seven lepromatous patients who developed ENL during the course of the study showed increases in both the Leu-3a:Leu-2a ratio and the number of IL 2-positive cells. IL 2-positive cells comprised 0.3% of the cells in all of the ENL lesions studied as compared with the 0.03% found in nonreactional lepromatous lesions (P less than 0.001). Lepromin-induced suppression of the Con A response, present in nonreactional lepromatous patients, significantly decreased in patients developing the ENL reaction, but returned after recovery from ENL. These changes in tissues and peripheral blood suggest that the pathogenesis of ENL is related to cell-mediated immune processes. Despite these immunologic changes, however, ENL patients do not recover antigen-specific skin tests or eliminate Mycobacterium leprae.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416837

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  T cell and cytokine patterns in leprosy skin lesions.

Authors:  P A Sieling; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Epidermal keratinocyte Ia expression, Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy.

Authors:  T H Rea; J Y Shen; R L Modlin
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions.

Authors:  P Sreenivasan; R S Misra; D Wilfred; I Nath
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

Review 4.  Immunopathology of leprosy granulomas.

Authors:  R L Modlin; T H Rea
Journal:  Springer Semin Immunopathol       Date:  1988

5.  A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum.

Authors:  E Filley; A Andreoli; J Steele; M Waters; D Wagner; D Nelson; K Tung; T Rademacher; R Dwek; G A Rook
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

6.  Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral therapy.

Authors:  Alexia Cusini; Huldrych F Günthard; Rainer Weber; Milo Huber; Jivko Kamarashev; Barbara Bertisch; Silke Peter; Bernhard Beck
Journal:  BMJ Case Rep       Date:  2009-12-01

Review 7.  Leprosy.

Authors:  R C Hastings; T P Gillis; J L Krahenbuhl; S G Franzblau
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

8.  Expression of adhesion molecules in leprosy lesions.

Authors:  L Sullivan; S Sano; C Pirmez; P Salgame; C Mueller; F Hofman; K Uyemura; T H Rea; B R Bloom; R L Modlin
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

Review 9.  Current concepts in the pathogenesis of leprosy. Clinical, pathological, immunological and chemotherapeutic aspects.

Authors:  W M Meyers; A M Marty
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

10.  Sera of leprosy patients with type 2 reactions recognize selective sequences in Mycobacterium leprae recombinant LSR protein.

Authors:  S Singh; N P Narayanan; P J Jenner; G Ramu; M J Colston; H K Prasad; I Nath
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.